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Migraine with aura may 
induce a seizure, and a 
seizure can be preceded 
or followed by a headache, 
which is often migrainous. 
Common pathophysiological 
factors could be 
responsible for this 
comorbidity. In monogenic 
subtypes, a shared 
genetic susceptibility 
cannot be excluded. 
See p 2-5
Although information on 
medical conditions is widely 
available and huge efforts 
have been made to sensitize 




The few clinical studies 
especially addressing 
older people show that 
both seizure control and 
drug tolerability decrease 
with advancing age when 
using standard therapies.
p 8-9
Levetiracetam is the first 
of the new generation 
AEDs to demonstrate a 
non-inferior efficacy and a 
more favourable tolerability 
compared to carbamazepine 
when used as monotherapy 
in adults with partial 
onset or generalized 
tonic-clonic seizures.
p 10-12
HYPOTHETICAL CO-MORBIDITY MODELS  
APPLIED TO EPILEPSY & MIGRAINE
Given the phenotypic and espe-
cially the genotypic heterogene-
ity of both disorders, one single 
explanation for the co-morbid-
ity is unlikely. Albeit, several ex-
planatory hypotheses have been 
proposed.
Shared genetic abnormalities have been 
identified in the rare monogenic forms 
of migraine. However, the common 
forms of migraine with or without aura, 
are complex polygenic disorders, as are 
several of the epileptic syndromes. To 
explore the “Common Genetic Risk Fac-
tors” hypothesis, Ottman and Lipton44 
assessed the risk of migraine in relatives 
of probands (n=1967) with genetic ver-
sus non-genetic forms of epilepsy, using 
two proxy measures of genetic suscepti-
bility: a 1st degree family history of epi-
lepsy and idiopathic/cryptogenic (versus 
postnatal symptomatic) etiology. Nei-
ther of these two measures was associ-
ated with risk of migraine in relatives. 
Furthermore, they also assessed the risk 
of epilepsy in the relatives of probands 
with versus without migraine. With the 
exception of one subgroup (sons of fe-
male probands), the risk of epilepsy in 
relatives was not associated with the 
proband’s history of migraine. Although 
these results do not rule out that the 
hypothesis of a shared genetic suscep-
tibility may apply to some subgroups of 
the disorders, they do not support this 
model as a global explanation for mi-
graine-epilepsy co-morbidity.
ShArED GENETIC SuSCEpTIbILITy
Migraine and epilepsy together account for 
up to 40% of all neurological consultations. 
On the one hand, almost 18% of females and 
6% of males suffer from migraine.1,2,3  On the 
other hand, with a prevalence of ± 0.6%, epi-
lepsy is one of the most prevalent neurologic 
disorders.4 Despite these high prevalences ob-
scuring the general overview, two decades ago 
1992 Andermann and Andermann5 showed 
that the prevalence of epilepsy (median 5.9%; 
range 1-17) in migraineurs greatly exceeds the 
one found in the general population of 0,5%. 
Since then a statistically significant association 
between migraine and epilepsy has been con-
firmed in several studies.6
Migraine and epilepsy share many similarities. 
Both are genetically-determined chronic par-
oxysmal disorders characterised by episodic 
attacks with absent or ill-defined interictal 
symptoms. The sensory, motor and cognitive 
characteristics of migraine and epilepsy may 
overlap. Aura, hallucinations, changes in mood 
and behaviour or consciousness, and focal sen-
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Epilepsy is by far the most frequent disorder comorbid with migraine. 
The exact causes of the comorbidity are unknown. In most cases, it 
seems likely that common pathophysiological factors related to cortical 
dysexcitability and thalamo-cortical rhythms are responsible for the 
association between the two disorders. In monogenic subtypes, a shared 
genetic susceptibility cannot be excluded. Although migraine with aura 
may induce a seizure, much more frequently a seizure can be preceded 
or followed by a headache which is often migrainous. Such peri-ictal 
headaches may bias studies on the prevalence of a comorbid association 
between migraine and epilepsy.
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Some genetic abnormalities, e.g. ATP1A2 
mutations, may favour subtypes of mi-
graine such as familial hemiplegic mi-
graine (FHM) and subtypes of seizures.20,21 
FHM and convulsions may also occur as al-
lelic disorders, due to different mutations 
of the same gene, e.g. on the CACNA1A 
gene. Moreover, heterozygous mutations 
in the glutamate transporter EAAT1 gene 
may also be associated with hemiplegic 
















Epilepsy could induce migraine headaches 
by activating the trigeminovascular system. 
Conversely, migraine could favour epilepsy 
by injuring the brain. This could explain the 
increased incidence of white matter lesions 











An example of a shared environmental risk 
factor explaining the co-morbidity, is head 
trauma, as it can trigger the appearance of 
both migraine and epilepsy.
Based on certain experimental data and the 
fact that anticonvulsants are effective in 
both diseases, e.g. cortical hyperexcitabil-















The increased risk of stroke and CV dis-
ease seen in women suffering from mi-
graine with aura18 could be attributed to 
an unidirectional reciprocal influence. But 
once again, this explanation is unlikely to 
apply to most patients. It would indeed 
imply that one disorder should precede 
the other, whereas in fact, there is an ex-
cess risk of migraine both before and af-
ter epilepsy onset.19
The third model, assuming the existence 
of “Shared Environmental Risk Factors”, 
cannot account for the increased risk of 
migraine in subjects with idiopathic or 
cryptogenic epilepsies.
Finally, the “Common Pathophysiologi-
cal Factor” model is the most attractive. 
However, in our opinion cortical hyperex-
citability is not a satisfactory explanation, 
as not all AEDs are effective in migraine 
prevention and as between attacks, the 
cerebral cortex in migraineurs is charac-
terised by a more complex dysexcitabil-
ity, chiefly dishabituation, instead of a 
simple hyperexcitability.50
Migraine and epilepsy
sory or motor symptoms may occur in both 
conditions. Both disorders may present with 
headache, as many patients complain of head-
ache before, during and after seizures. More-
over, in some patients, the migraine aura can 
trigger seizures.7 Although migraine and epilep-
sy can independently from each other coexist 
in one subject, at least six clinical syndromes 
associating migraine with epilepsy have been 
described.8
Enhanced migraine risk in 
epileptics
A large epidemiologic survey, based on data of 
the Epilepsy Family Study of the Columbia Uni-
versity, found a history of migraine in 24% of 
the epilepsy probands and in 26% of their rela-
tives with epilepsy versus only 15% in relatives 
without epilepsy.9 After correction for years at 
risk and gender, the rate ratio for migraine was 
2.4 (95% CI, 2.02 to 2.89) among probands and 
2.4 (1.58 to 3.79) among relatives with epilep-
sy, compared with relatives without epilepsy. 
Although the migraine risk was highest in pro-
bands with epilepsy due to a head trauma, af-
ter stratification by seizure type, age at onset, 
etiology of epilepsy, and history of epilepsy in 
first-degree relatives, it was significantly higher 
in every subgroup of probands compared to 
unaffected relatives. Among probands the age-
specific incidence of migraine was increased to 
a greater extent after onset of epilepsy than 
before. However, it was also significantly in-
creased in the 5 years prior to onset and even 
in the years before.
A recent large analysis of data from two Cana-
dian health surveys, evaluating the prevalence 
of epilepsy and 19 other chronic conditions, 
concluded that epilepsy patients had a statis-
tically significant higher prevalence of most 
chronic conditions than the general popula-
tion.10 Migraine was found at a prevalence of 
185 per 1000 epileptics, twice as frequent as 
in the general population (RR 2.6, 95% CI 2.2-
3.0). When gender was taken into account, mi-
graine was one of 4 most frequent comorbid 
conditions in females with epilepsy (RR 2.4, 
95% CI 2.1-2.7).
Usefulness of comorbidity studies
•  Differential patterns of comorbidity among subtypes of a particular index 
disorder may unveal the existence of different forms of the condition.
•  Differential associations between particular pairs of diseases may yield 
clues regarding the pathogenesis of the index disease. 
•  If two conditions emanate from common underlying etiologic factors, 
investigations can be targeted to common risk factors. 
•  If the comorbid disorder is caused by the index disease, prevention of the 
secondary conditions might be possible. 
Nevertheless, which conceptual or clinical advantages arise for either 
disorder from the studies on comorbidity of migraine and epilepsy is not 
clear yet.
And more epilepsy in (some) 
migraineurs
The prevalence of epilepsy in people with mi-
graine varies from 1% to 17% (median 5.9%), 
which is substantially higher than the popula-
tion prevalence of epilepsy. However, in a re-
cent study of Finnish migraine families only 
male patients suffering from migraine with 
aura reported a significant association with 
stroke and epilepsy (OR 6.76, 95% CI 1.028-
44.48), while there was no association with 
other subtypes of migraine in men or with 
any subtype in women. In the total population 
of migraineurs the most frequent associated 
disorders were hypotension (OR 1.43, 95% CI 
1.02-2.01), allergy (OR 1.83, 95% CI 1.34-2.51) 
and psychiatric disorders (OR 4.09, 95% CI 
2.11-7.92).11
Comorbidity in childhood
The distinctive features of migraine have been 
found in several pediatric epilepsy syndromes. 
These include benign epilepsy of childhood 
with occipital spike-waves complexes,12 benign 
rolandic epilepsy with migraine,13 mitochon-
drial encephalomyopathy with lactic acidosis 
and strokes (MELAS),14 basilar migraine with 
seizures and migraine with primary generalized 
absence epilepsy.15
Regarding benign rolandic epilepsy of childhood 
(BREC), literature data are conflicting. Studies 
showing an association with migraine16,17,18 and 
studies denying it  have been published. For in-
stance, Giroud16 compared the incidence of mi-
graine in four groups of children: 28 children with 
absence epilepsy, 42 with BREC, 38 with another 
partial epilepsy and 30 with head trauma. The 
incidence of migraine in BREC was 62%, com-
pared with 34% in children with absence epi-
lepsy, 8% in those with partial epilepsy, and 6% 
in those with a history of head trauma. Bladin20 
followed 30 cases of BREC and noted that 20 
(67%) patients developed recurrent headaches 
during the course of the epilepsy and 24 (80%) 
typical migraine after remission of BREC. An as-
sociation with migraine has also been reported 
for other benign partial epilepsies of childhood 
such as benign occipital epilepsy.21,22 
All these studies were limited, however, by 
lack of sensitive diagnostic criteria for child-
hood migraine. By using revised Interna-
tional Headache Society (ICHD-II) criteria,23 
Wirrell and Hamiwka24 compared the preva-
lence of migraine in 3 age- and sex-matched 
cohorts of 53 children: children with BREC, 
those with cryptogenic/symptomatic par-
tial epilepsy and those without epilepsy. 
Children with BREC had higher rates of mi-
graine (p=0.05), and of migraine equivalents 
excluding motion sickness (p<0.005) than 
those without seizures. But as they did not 
differ significantly from the cryptogenic/
symptomatic partial epilepsy cohort, the 
authors concluded that partial epilepsy, re-
gardless of etiology, is associated with higher 
rates of migraine in children. 
There is also some evidence that children with 
migraine are more likely to have benign focal 
epileptiform discharges on their EEG, but these 
children have no clinical seizures25,13 and the 
precise significance of the EEG abnormalities 
is unknown. 
Temporal coincidence of 
headache and epilepsy
According to the new IHS classification (ICHD-
II : code 1.5.5), migraine-triggered seizures, the 
so-called “migralepsy” (Douglas Davidson)23 
only occur in migraine with aura, either dur-
ing or within one hour after the aura. As the 
seizures may overshadow the migraine, the 
latter are easily overlooked by both patients 
and physicians. There are also very rare case 
reports of headache as the sole or most pre-
dominant clinical manifestation of an epileptic 
seizure.26
Although very common, peri-ictal headaches 
are also often neglected because of the dra-
matic neurologic manifestations of the seizures 
themselves and the frequent inability of the 
patient to fully observe or recall these head-
aches.
In a systematic study of the clinical character-
istics and lateralizing value of ictal and in par-
ticular pre-ictal headache (PIHA) in intractable 
partial epilepsy, 59% of patients reported re-
current headache and 11% had pre-ictal head-
ache.27 Among the latter 7% suffered from 
early PIHA (< 30 minutes before seizure onset) 
and 4% of prodromic PIHA (24 hours to 30 
minutes before seizure onset). In all 11 patients 
with PIHA, the headache was fronto-temporal 
and fulfilled the diagnostic criteria for migraine 
without aura in 4 patients (36%) (2 with early 
PIHA, 2 with prodromic PIHA). Ten patients 
with PIHA (90%) had temporal lobe epilepsy 
(TLE) and 8 (72%) had generalized tonic-clonic 
seizures. Of the 10 patients with TLE and PIHA, 
9 suffered from pain ipsilateral to the epilep-
tic focus. All patients with PIHA had a positive 
family history of migraine. After surgery, the 
headache disappeared in all 7 patients who 
became seizure-free and in 1 patient who had 
a subtotal remission. Only 1 patient with rare 
seizures continued to have PIHA. The authors 
hypothesize that vasodilatation and reactive 
hyperemia at the site of the discharging epilep-
tic focus might be responsible for the ipsilateral 
migraine-like headache. 
In Karaali-Savrun’s study6 pre-ictal headache 
was present in 20 out of 109 patients (14.81%) 
with cryptogenic focal and generalized sei-
zures epilepsy. It was localized to the forehead, 
throbbing in quality, moderate in intensity and 
significantly more frequent prior to any type 
of secondary generalized tonic-clonic seizure in 
comparison to other seizure types.
Similar results were found in another study of 
intractable partial epilepsy29: 47 out of 100 pa-
tients (47%) had peri-ictal headache: 11 pre-
ictal, 44 post-ictal and 8 both pre- and post-
ictal headache. In 90% of patients (27/30) 
with temporal lobe epilespy (TLE) the peri-ictal 
headache was ipsilateral to the seizure focus 
while in extratemporal epilepsy (ETE) only 2 
out of 17 patients (12%) had ispsilateral head-
aches (p<0.001). The peri-ictal headaches had 
the characteristics of migraine without aura 
in 18 of 30 (60%) patients with TLE and in 7 
of 17 (41%) of those with ETE (p=0,24). How-
ever, in another study30 migraine-like peri-ictal 
headache was also ipsilateral in patients with a 
seizure focus in the occipital lobe. 
A comparable overall incidence of seizure-as-
sociated headaches was found in a study of 
110 outpatients from an epilepsy referral cen-
ter.31 Forty-seven (43%) reported headache 
associated with their seizures, 43 exclusively 
post-ictal headaches, but only 1 exclusively 
pre-ictal headaches. Three patients had both 
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Pre-ictal headaches are relatively rare and short–lived. They occur in 
± 10-15% of patients, seem more frequent in focal epilepsies (tempo-
ral and occipital) and are usually ipsilateral to the epileptic focus.
pre- and post-ictal headaches. In the major-
ity of patients, post-ictal headaches occurred 
in more than 50% of the seizures. Post-ictal 
headaches were associated with focal seizures 
in 23 patients and/or with generalized seizures 
in 54 patients. According to IHS criteria, the 
headaches were classified as migraine-like in 
34% of patients and as tension-type headache 
in 34% of patients; they could not be classified 
in 21% of patients. There was no relationship 
between the localization of the epileptogenic 
focus, localization of the headache, or the 
headache classification.
possible mechanisms of the 
migraine-epilepsy interactions
Except for seizures triggered by a migraine 
aura, the mechanisms underlying seizure-re-
lated pre-ictal headaches are poorly under-
stood. One may speculate that a thalamocor-
tical dysrhythmia preceding the seizure onset, 
or endogenous/environmental factors able to 
trigger a seizure (e.g. stress or exteroceptive 
stimuli) may favour headache. It is noteworthy 
that primary headaches such as migraine and 
tension-type headache are more prevalent in 
the perimenstrual period in epileptic women 
with menstrually-related seizures.
Concerning post-ictal headaches, there are 
good reasons to believe that these are due to 
an activation of the trigeminovascular system, 
which is the major pain-signalling system of 
the viscera brain. This probably explains why 
most of these headaches have migrainous fea-
tures and why they may overlie the epileptic 
focus. In patients who report post-ictal ten-
sion-type like headaches, strain in neck mus-
cles during the seizure may play a pathogenic 
role. Unfortunately, post-ictal headaches are 
undertreated, as for instance information on 
the therapeutic effectiveness of migraine-spe-
cific drugs such as triptans, is lacking.
Other pathophysiological factors involved in 
migraine may be relevant: for instance, several 
lines of evidence, coming from morphological, 
biochemical, imaging and genetic studies, sug-
gest that at least some subtypes of migraine 
may be related to a mitochondrial defect.33 This 
might explain why enhancers of mitochondrial 
metabolism, such as riboflavin and co-enzyme 
Q, are effective in migraine prevention.34,35 Im-
paired mitochondrial energy mechanisms may 
favour seizure activity by various molecular 
mechanisms and mitochondrial cytopathies 
may classically express themselves phenotypi-
cally as a combination of migraine with aura, 
epilepsy and strokes.36,37 Interestingly, in Ott-
man & Lipton’s study44 sons of migrainous fe-
male probands had an increased risk of epilepsy 
which might be related to maternal transmis-
sion of a mitochondrial defect.
Abnormalities of scalp-recorded high frequen-
cy oscillations in evoked cortical potentials 
have been found in migraine between attacks.38 
These oscillations reflect activity in thalamo-
cortical circuits, which are also involved in the 
pathogenesis of seizures. Thalamo-cortical 
dysrhythmia could thus be a common phe-
nomenon to both disorders.
Implications for therapy
If migraine and epilepsy are comorbid in a pa-
tient, an anticonvulsant effective in migraine 
prevention should be preferred. As anticonvul-
sants are generally less well tolerated in mi-
graineurs than in epileptics, a slow dose escala-
tion is mandatory in migraine, as is the search 
for the lowest efficacious dose. 
While the classical anti-epileptic drugs such as 
phenobarbital, phenytoin or carbamazepine, 
have no profylactic effect in migraine, valproic 
acid and topiramate surely have (grade I evi-
dence). Up to now, there is only circumstancial 
evidence suggesting efficacy for gabapentin, 
levetiracetam, tiagabide and zonisamide. La-
motrigine, one of the most effective strategies 
for the prevention of migraine with aura39,40, 
lacks efficacy in migraine without aura41, which 
represents 80% of all migraines. This observa-
tion on its own indicates that explaining the 
migraine-epilepsy comorbidity by cortical hy-
perexcitability is not reasonable.
Finally, adequate treatment for postictal head-
aches should be provided in epileptic patients. 
One should not refrain from using triptans, if 
the headaches are migrainous.
Further studies are clearly needed to better 
understand the genetic, pathophysiologic and 
therapeutic interplay between migraine and 
epilepsy.
References: see page 8
Post-ictal headaches are more prevalent (from 23.8% to 
48%) and may last for several hours. Post-ictal headache is 
migraine-like in 25.9% to 69% and occurs more frequently 
in patients with a positive history of migraine.28 It can be 
disabling and affect the patient’s quality of life. It is generally 
undertreated.31
Post-ictal headache occurs more often after secondary 
generalized tonic-clonic seizures, in whitch case it usually lacks 
migrainous characteristics. Although partial epilepsies are less 
associated with post-ictal headache, the latter are more often 
migraine-like and ipsilateral to the epilleptic focus, especially 
in occipital lobe epilepsy.30
Migraine and epilepsyComorbid migraine appears to worsen  
the prognosis of epilepsy
Of the few studies addressing the prognosis of migraine and epilepsy in co-
morbid patients, the publication by Velioglu32 provides the most informative 
and reliable results. Two matched cohorts of epileptic patients, one with 
epilepsy-migraine comorbidity (n=59), the other with only epilepsy (n=56), 
were prospectively followed for 5-10 year. The epilepsy-migraine group 
had a significantly lower cumulative probability of being seizure-free (46%) 
over 10 years, compared to the epilepsy only group (12%). Moreover, the 
epilepsy-migraine group had a significantly longer duration of epilepsy, a 
lower early treatment response, a higher incidence of intractable epilepsy, 
a higher need for polytherapy to achieve remission, and more problems for 
seizure control and medication for at least the last 2 years of follow-up.
an inconvenient true
As many still think about epilepsy as a nec-
essarily handicapping, hardly treatable and 
even uncurable disease, patients as well 
as their families experience epilepsy as a 
stigma, starting from the diagnosis on. Con-
fronted with such misconceptions, patients 
refrain from outing themselves as “epilep-
tics”. Another reason making epilepsy a “hid-
den” disease, is the advent of highly effective 
anti-epileptics. Years ago, seizures were not 
that rare. Today, only few people have ever 
witnessed a full clonic-tonic seizure followed 
by unconsciousness, as most patients remain 
seizure-free for most of the time. 
As a consequence, a patient having a seizure 
in public, is stared at by a horrified crowd. 
Even before the patient can take notice, he 
is hurried away by ambulance towards the 
emergency department of the nearby hospi-
tal. This explains why in Belgium, neurologists 
see a lot of reluctant epilepsy patients, who 
don’t really want, neither need specialised 
help, as for patients with occasional seizures 
under treatment, a hospitalization is seldom 
mandatory. 
Echeloned care is a fact
An epilepsy patient spontaneously seeking 
specialised help, is rather uncommon. Even 
when confronted with partners or parents 
who witnessed the seizure, they often tend 
to minimize the extent of it or even deny it 
completely. The normal caregiving pathway 
begins at the GP, who usually suspects the 
diagnosis of epilepsy based on clinical signs 
only. The diagnosis will then be evidenced 
and documented by the second line neurolo-
gist by means of advanced medical imaging, 
EEG… For a first seizure, hospitalization even-
tually makes sense to fine-tune the diagnosis 
and start an adequate treatment. The last 
decade, medication became more and more 
In spite of efforts and achievements.
Epilepsy: an inconvenient true.
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In the past decades enormous progress has been made in the diagnosis and especially the therapy of 
epilepsy. Valuable campaigns to inform and sensitize the population about epilepsy have been launched. 
Today, information on medical conditions is available to all on a scale never seen before… So what went 
wrong, as questions, prejudices and misunderstandings about epilepsy still remain?
Paul Bourgois, MD
Department of Neurology, 
AZ Groeninghe, Kortrijk
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a specialist’s task, as most GPs do not feel very 
comfortable with the abundance of new anti-
epileptic drugs available today. Once stabilized 
under therapy, the patient’s follow-up is as-
sumed by his GP, as a once-a-year check by the 
neurologist is generally sufficient.
Finally, second line neurologists refer some pa-
tients with diagnostic problems or unrespon-
sive to standard treatments (and occasionally 
patients who want a second opinion) to the 
next level. It is obvious for third line centres 
to dispose of more sophisticated diagnostic 
tools such as video monitoring of seizures, 
PET-scan… and highly specialised therapeu-
tic techniques, e.g. vagal nerve stimulation or 
neurosurgery. Nowadays, institutionalisation 
is restricted to the rare cases needing adjusted 
care because of extremely therapy resistance 
and/or concomitant mental retardation.
Echeloned information is still a 
challenge
So the good news is that we dispose of skilled 
GPs and specialists, well-equiped centres, ef-
ficacious medications and streamlined caregiv-
ing pathways, respecting everyone’s role and 
competences. But although we are living in the 
so-called “information era”, ignorance about 
this disease still rules. Today’s patients indeed 
can surf on the word wide web, but internet 
is not always a very reliable source. Moreover, 
as epilepsy has many faces, patients easily go 
astray in the overwhelming bulk of information 
available. Based on our own experience with a 
brochure we made for our Stroke Unit patients, 
we think that in this respect an objective and 
concise booklet could be of great help.
To avoid the unnecessary burden on the emer-
gency department every time someone has a 
seizure in public, at the population level, epi-
lepsy should no longer be a taboo. Once epi-
lepsy has become accepted, patients will be 
less reluctant to out themselves as epileptics. 
Nowadays, some patients deliberately ignore 
the ban on driving, endangering their own and 
others’ lives, just because they can’t bear the 
idea that someone could ask them for an ex-
planation why all of a sudden they no longer 
have a driving license. 
At the level of the patient’s immediate entou-
rage, including colleagues at work or teachers 
at school, precise information explaining the 
do’s and don’ts in case of a seizure, should be 
available. 
And finally, for the patients themselves and 
their family, a generic list of topics is mandato-
ry, as our experience shows that each time we 
see a newly diagnosed patient, the same ques-
tions about prognosis, therapeutic possibilities, 
school performances, job opportunities… arise.
Assignments for first line 
caregivers
Inform and above all, counsel 
family members
Check compliance
phenytoin, carbamazepin and 
valproate blood levels can be 
determined 
emphasize the importance 
of sleeping times and alcohol 
withdrawal
make sure a patient respects a 
car driving ban
Look forward
screen for medication side  
effects
ask proactively about behaviour 
and achievements at  
school/work
warn patients for possible 
pharmacological interactions 
discuss (anti)conception before 
the patient is pregnant
an inconvenient trueCALL For WITNESSES
A clear and detailed description of the seizure can be crucial for assessing 
the seizure type and can even reveal  important clues for localizing a fo-
cus. In the past, it was proven to be useful asking parents to record their 
convulsing children on video.
An even better approach would be to “professionalize” the entourage at 
a point they can recognize diagnostic relevant features. 
In our Neurology Department we assessed the feasibility of such ap-
proach starting with our own in-house nursing staff. To sharpen the 
awareness of the paramedics for diagnostic clues, while coping with sei-
zures, we developed  a tailor-made course. The didactic qualities of this 
new learning tool where evaluated by asking the nurses to describe three 
different seizure types recorded on a DVD, before and after completion 
of their course. 
It was just astonishing to notice how much more details were notified: 
the coloration of the skin, the deviation of the eyes, the extent of the 
myoclonies, the duration of the unconsciousness, the presence of urinary 
incontinence…
In a next step, the acquired skills were implemented in daily practice. By 
means of a custom form the observations during a seizure are recorded in 
a standardized way. This allows the attending neurologist to make a more 
precise evaluation of the type and extend of the seizure.
 
Encouraged by the enthusiastic and convincing experiences within our 
own department, now other departments also tend to adopt the same 
procedure.
SElf-hElP IS UNDErwAy
As a professionally assisted patients organization, among other tasks, 
the Vlaamse Liga tegen Epilepsie/Ligue francophone belge contre l’épilepsie 
provides epilepsy patients and their families with specific information 
about social problems encountered by patients with epilepsy (insurance, 
family, school, job...). for information seekers, a glance at their site is 
recommended:  http://www.ligueepilepsie.be/fr/
 http://www.epilepsieliga.be/files/info/home.php
AEDs in elderly people
In the Veterans Affairs Cooperative Study 1, a 
randomized, double-blind, double dummy, par-
allel study, 593 older individuals, on average 72 
years old, with newly diagnosed seizures were 
assigned to standard therapy with carbamaze-
pine, gabapentin or lamotrigine. With respect 
to seizure control at 12 months, the overall re-
sults showed little difference among groups. 
But what is more interesting, when dividing 
the study population into three age groups, the 
intent to treat seizure free rate at 12 months 
showed a steady decline from the youngest 
to the oldest group for all three treatments. 2 
(See Table)
As could be expected, due to their supe-
rior tolerability, the patients randomized to 
the newer AEDs gabapentin and lamotrigine 
demonstrated a significantly better one-year 
retention versus carbamazepine (difference 
in termination for adverse events p=0.0001). 
However, sedation, which was an important 
side effect in this study population, showed a 
steady increase in age-related incidence also 
for the lamotrigine and gabapentin groups. In 
particular, two-thirds (65.6%) of the gabapen-
tin 80+ group reported sedation, compared 
with just over half that number (34.4%) for 
the 60-69 group. 
risk for drug-drug interactions 
underestimated 
Another problem often encountered in the 
elderly is the risk for interactions with con-
comitant medication. A retrospective cohort 
study in epilepsy patients based on a US claims 
database (2001-2004) confirmed that elderly 
people taking AEDs are at increased risk for 
AEDs in elderly people.
Age inversely correlated to 
efficacy and tolerability.
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Although new onset epilepsy in the elderly is far from uncommon, only 
few clinical studies especially addressing elderly people are carried out. 
Nonetheless, using established standard therapies, both seizure control 
and drug tolerability decrease with advancing age.
Irrespective of the AED used,
seizure free rates are declining with age
60-69 yrs 70-79 yrs 80+ yrs
carbamazepine 27.6 21.4 17.1
gabapentin 20.3 27.8 17.1
lamotrigine 32.9 27.1 20.7
exposure to medications that may incur a po-
tentially adverse pharmacokinetic interaction. 3 
(See Table)
As expected, the risk of addition of concomitant 
medication at some time after an AED is initi-
ated, is inversely related to the patient’s gen-
eral health condition. However, independently 
from co-morbidities, the risk of drug-drug in-
teractions shows significantly higher in females 
and also increases with advancing age. These 
real life findings emphasize the importance of 
avoiding enzyme inducing antiepileptic drugs, 
especially in aging, female patients, irrespec-
tively of their general health condition.
Levetiracetam is efficacious, well 
tolerated…
The above mentioned problems arising in older 
epilepsy patients explain the interest in novel, 
well tolerated AEDs such as levetiracetam. A 
first study of which the results were present-
ed, was an open label trial evaluating the ef-
ficacy and safety of low dosed levetiracetam 
as monotherapy in elderly patients with cryp-
togenic epilepsy. 4 New onset epilepsy in older 
people is often cryptogenic as the seizures oc-
cur without a defined provoking factor or with-
out an obvious remote or current neurological 
pathology.
Fourteen patients > 60 years old (mean age 68 
years), newly diagnosed for cryptogenic epilep-
sy and having experienced at least 2 seizures, 
were enrolled. Starting at 250 mg/day, leveti-
racetam was uptitrated by 250 mg a week. Ev-
ery 3 months all patients performed a visit to 
access efficacy and safety through neurologi-
cal examination, seizure diary, EEG, complete 
blood test, MMSE, SF12, NPI... 
All patients completed the study. After a follow-
up of 12 months, they all became seizure free: 
8 patients at 1000 mg/day and 6 patients who 
needed a higher dose (up to 2000 mg/day) for 
seizure control. Levetiracetam also proved to 
be well tolerated without any interaction with 
other concomitant treatments. Most often en-
countered adverse effects were somnolence, 
dizziness, headache, agitation and irritability, 
all mild and limited in time. Moreover, after le-
vetiracetam treatment, all patients showed an 
improvement in quality of life as their level of 
autonomy and relationships increased. 
… and improves QoL in the 
elderly
The efficacy and the superior tolerability of le-
vetiracetam in elderly epileptic patients were 
confirmed in a second study with carbam-
azepine as a comparator. 5 Indeed, the reten-
tion in the study was significantly higher for 
levetiracetam than for carbamazepine. The 
efficacy of both study drugs showed similar, 
but carbamazepine caused significantly more 
side effects, resulting in earlier termination of 
treatment.
In this trial, 24 consecutive, newly diagnosed 
outpatients who experienced at least two un-
provoked seizures in the past 12 months were 
randomized to monotherapy with 1000 mg 
levetiracetam/day or 600 mg carbamazepine/
day. Nine out of 24 patients (6 in the levetirace-
tam group and 3 in the carbamazepine group), 
showed minimal EEG abnormalities at basal 
evaluation consisting of focal theta waves, that 
disappeared after 12 weeks of treatment in all 
patients.
All patients but 3 (2 on carbamazepine and 1 
on levetiracetam) became seizure-free for 48 
weeks of follow up. In the non-responders, the 
dosage was subsequently increased to respec-
tively 800 mg and 1500 mg a day. All leveti-
racetam treated patients completed the fol-
low up period remaining on the original drug, 
achieving a 100% retention rate. On the other 
hand, 3 patients on carbamazepine discontin-
ued their therapy for side effects (2 patients 
with marked somnolence and one patient with 
dizziness). These results also suggest that the 
optimal dose of both drugs may be lower in 
elderly compared with the general epileptic 
population.
Once again an impressive difference in the im-
pact of drug on quality of life was noticed. The 
SF-36, administered at baseline and through-
out the study, showed a poor impact of treat-
ment on quality of life in all levetiracetam 
patients, while 4 out of 12 carbamazepine pa-
tients showed a worsening in several items of 
the questionnaire.
hazard ratio of first addition of medication possibly causing 
pharmacological interactions in elderly epilepsy patients
Covariates HR [95% CI]
Male (vs female) 0.8 [0.772;0.828]
Age
 18-34 (vs 0-17) 1.112 [1.059;1.169]
 35-54 (vs 0-17) 1.379 [1.317;1.443]
 55-64 (vs 0-17) 1.636 [1.532;1.746]
 65+ (vs 0-17) 1.749 [1.574;1.944]
General health condition
 mildly affected (vs good) 1.434 [1.361;1.512]
 severely affected (vs good) 1.536 [1.450;1.629]
All p-values <0.001
1  Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, 
Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks 
W, Felicetta J, Tomyanovich ML; VA Cooperative Study 428 
Group. New onset geriatric epilepsy: a randomized study 
of gabapentin, lamotrigine, and carbamazepine. Neurology 
2005;64(11):1868-1873
2  Rowan AJ, Ramsay RE, Macias F, VA Cooperative Study #428 
Group. In the elderly, seizure control and antiepileptic drug 
tolerance decrease with increasing age. Poster Number: 2.230
3  French J, Grossman P, Gidal B, Le Teuff G, Bugli C. Potential 
Drug Interactions in Epilepsy Patients: Risk of Concomitant 
Medication Use. Poster Number: 2.223
4  Barbato G, Alfieri P, Arlomede R, Visco G, Terracciano AM. 
Elderly Patients with Cryptogenic Epilepsy Treated with Leve-
tiracetam as Monotherapy. Poster Number: 2.104
5  Paciello N, Marchi PN, Chiummiento M,Mazza S, Paciello M. 
Levetiracetam vs Carbamazepine in Epileptic Elderly Patients. 
Poster Number: 2.144
AEDs in elderly people
Levetiracetam as starter therapy
As more than 50% of patients with newly di-
agnosed epilepsy will achieve adequate seizure 
control with only one antieplipetic drug, mono-
therapy is the treatment strategy of choice. For 
patients with partial epilepsy or generalized 
tonic-clonic seizures carbamazepine is a first-
line standard drug. Patients with generalized or 
multiple seizure types and patients without a 
clearly determined type of seizure or epilepsy 
syndrome at the time of treatment initiation 
are mostly treated with valproic acid.
These older medications are certainly useful. 
But as they are not devoid of potentially haz-
ardous side effects, in particular their propensi-
ty to cause neurotoxicity, alternative treatment 
options are more than welcome. Ideally, the 
new generation antiepileptics will allow us to 
deal with possible drug-drug interactions and 
contraindications, to obtain a quicker onset of 
action or to adopt easier titration schedules.
A potent broadspectrum 
antiepileptic
In the studies published up to now, levetiracetam 
appears as a potent antiepileptic, controlling a 
broad range of seizure types. Moreover, it is de-
void of the drug-drug interaction seen with older 
AEDs and it can rapidly be uptitrated to thera-
peutic doses. In the mean time it has also proven 
its efficacy and safety in so-called “special pop-
ulations” such as in the elderly1, and it offers a 
therapeutic option in young women at childbear-
ing age, as it does not interact with hormonal 
anticonceptives. Preliminary data that still need 
confirmation on a larger scale even suggest that 
it might be devoid of teratogenic effects.2 
In the past, levetiracetam has already proven its 
efficacy as add-on therapy in adults as well as 
in children with partial and generalized seizures.3 
Levetiracetam has also been evaluated as initial 
monotherapy. This was done in 82 children and 
adolescents with newly onset epilepsy (exclud-
ing absences) at a mean dose of 21.8 mg/kg/day.4 
A retrospective review of their medical records 
revealed that 85.4% of these patients achieved 
at least 6-month seizure freedom. In this study 
only 4 patients discontinued their study drug 
due to levetiracetam imputable adverse events.5 
Established efficacy  
as first choice 
Up to now, levetiracetam has been registered 
as an adjunctive therapy in the treatment of 
partial onset seizures with or without second-
ary generalisation in patients with epilepsy 
and as adjunctive therapy in the treatment of 
myoclonic seizures in adults and adolescents 
from 12 years of age with Juvenile Myoclonic 
Epilepsy. But based on the results of a well-
conducted comparative monotherapy study 
in patients with newly or recently diagnosed 
epilepsy and suffering from partial or general-
ized tonic-clonic seizures (Study N01061)6, the 
current indication will be extended to mono-
therapy treatment of partial onset seizures 
with or without secondary generalisation in 
patients from 16 years of age with newly diag-
nosed epilepsy.
The LEV N1061 study is a randomized, double-
blind, head-to-head comparison study with 
carbamazepine-CR, the reference drug, held 
in adult patients with newly diagnosed partial, 
or generalized tonic-clonic epilepsy (exclud-
Benefits from levetiracetam 
as starter therapy in epilepsy.
Starter therapy 6
levetiracetam is the first of the new generation antiepileptic drugs to 
demonstrate a non-inferior efficacy to carbamazepine when used as 
monotherapy in adult patients with partial onset or generalized tonic-
clonic seizures and to show a significantly more favourable tolerability 
profile in a head-to-head study that used a rigorous non-inferiority design 
and an optimal use of the comparator.
B. Sadzot
Dept of Neurology, Epilepsy Unit, 
CHU Liège, Belgium
References
1.  Alsaadi TM, Koopmans S, Apperson M, Farias S. Levetiracetam mono-
therapy for elderly patients with epilepsy. Seizure 2004;13:58-60
2.  Hunt S, Craig J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell 
R, Irwin B, Morrison PJ, Morrow J. Levetiracetam in pregnancy: 
preliminary experience from the UK Epilepsy and Pregnancy Register. 
Neurology 2006;67:1876-1879
3.  Privitera M. Efficacy of levetiracetam: a review of three pivotal clini-
cal trials. Epilepsia  2001:42 (Suppl 2):31-35
4.  Sharp GB, Van Lierop AE, Shbarou RM, Atherton ME, El-Nabbout 
BH, Lange BM, Ionita CM: Levetiracetam monotherapy in new onset 
pediatric epilepsy. Scientific Exhibit, AES San Diego 2006
5.  Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, 
Gauer LJ, Lu Z; N159 Study Group.  Double-blind placebo-controlled 
trial of adjunctive levetiracetam in pediatric partial seizures. Neurol-
ogy 2006:66:1654-660
6.  Ben-Menachem E, Brodie MJ, Perucca E on behalf of the N01061 
Study Group. Efficacy of levetiracetam monotherapy; randomized 
double-blind head-to-head comparison with carbamazepine-CR in 
newly diagnosed epilepsy patients with partial onset or generalised 
tonic-clonic seizures. Presented at the American Academy of Neurol-
ogy, April 2006. European Journal of Neurology 2006;13 (s2):9-41.
ing idiopathic generalized epilepsy). The 576 
randomized patients were assigned to leveti-
racetam 1 000 mg/day or carbamazepine CR 
400 mg/day. This dose was maintained for a 
six-month evaluation period or until the next 
seizure. When a seizure occurred, doses were 
increased to levetiracetam 2 000 mg/day 
and carbamazepine CR 800 mg/day or leve-
tiracetam 3 000 mg/day and carbamazepine 
CR 1 200 mg/day. Once six-month seizure 
freedom was achieved, patients entered a six-
month maintenance period. 
better tolerated
In this trial levetiracetam demonstrated six- 
and 12-month seizure freedom rates of 73.0% 
and 56.6% respectively, when used as mono-
therapy in newly diagnosed patients, providing 
evidence that levetiracetam is as effective as 
carbamazepine-CR as first-line therapy for pa-
tients with partial or generalized tonic-clonic 
seizures. Moreover, levetiracetam was better 
tolerated than carbamazepine-CR as fewer 
patients receiving levetiracetam had adverse 
events leading to drug discontinuation or dose 
change (16.1% versus 23.0%, p=0.046).
Double-blind



















































EscV = Escalation Visit 
IV = Intermediate Visit
EV = Evaluation Visit








The primary objective was to prove that 
monotherapy treatment with levetiracetam 
1 000 to 3 000 mg/day is non-inferior to 
monotherapy with CBZ 400 to 1 200 mg/
day in achieving 6-month seizure freedom in 
adults (> 16 years old) with newly or recently 
diagnosed epilepsy, suffering from partial or 
generalized tonic-clonic seizures. The second-
ary objective was to compare the safety and 
tolerability of both drugs.
A total of 579 subjects with newly or recently 
diagnosed epilepsy having experienced at 
least 2 unprovoked seizures separated by a 
minimum of 48 hours in the year preceding 
randomization, of which at least 1 seizure oc-
curred in the last 3 months, were elegible for 
the study. They were randomized to receive 
either levetiracetam (n = 288) or controlled 
release carbamazepine (n = 291) as a compar-
ator. The ITT population totalled 576 patiens, 
285 in the levetiracetam group and 291 in the 
carbamazepine group.
The study consisted of several periods. After 
an initial 1-week screening period, the thera-
py was uptitrated during 2 weeks, followed by 
a 1-week stabilization period. Patients then 
started a regimen of carbamazepine CR 400 
mg/day or levetiracetam 1 000 mg/day and 
entered an evaluation period of 6 months.
If a seizure occurred during this 6-month 
evaluation period, a 2-week dose escalation 
period to the second target daily dose (car-
bamazepine CR 2 x 400 mg/day or levetirace-
tam 2 x 1 000 mg/day) was scheduled. After 
a 1-week stabilization period at the new dose, 
the patients once again entered a 26-week 
evaluation period. 
The patients experiencing a new seizure dur-
ing this second evaluation period were further 
uptitrated to the third target daily dose (car-
bamazepine CR 3 x 400 mg/day or levetirace-
tam 3 x 1 000 mg/day). Whatever dose was 
needed to control their seizures, all patients 
were observed during a maintenance period 
of 26 weeks, starting one week after the point 
of time the last efficacious dose was started. 
A study demonstrating efficacy and tolerability.
Levetiracetam as a first choice AED.
The pivotal comparative monotherapy study N01061 is a Phase III, 
multicentre, double-blind, randomized non-inferiority study evaluating 
the efficacy and the tolerability of levetiracetam in monotherapy, with 
carbamazepine as an active comparator, in newly diagnosed epilepsy 
with partial or generalized tonic-clonic seizures.*
For each subject, the 6-month observation period was defined as starting at the latest of the three 
following dates: Visit 3, or Escalation Visit 1 + 21 days or Escalation Visit 2 + 21 days. The end date 
of the 6-month seizure-freedom evaluation period was equal to the start date + 181 days, so that 
the number of evaluated days was 182.
STuDy N1061 DESIGN
* The EMEA’s Committee for Proprietary 
Medicinal Products (CPMP), advises that 
therapeutic confirmatory monotherapy 
studies in newly or recently diagnosed 
patients should always be randomized, 
double-blind positive controlled trials 
aiming to demonstrate at least a similar 
benefit/risk balance of a test product as 
compared to an acknowledged standard 
product at its optimal use.
Levetiracetam as starter therapy
oNGoING LEvETrIrACETAM STuDIES IN NEWLy DIAGNoSED 
EpILEpSy
At the end of this study the patients who continued the study drug, had three 
options for continuing: 
Switch to a double-blind levetiracetam/carbamazpine extension study 
1)  Study N01093, a double-blind long-term follow-up study in which subjects who 
benefited from their randomized treatment are able to continue their study 
drug. The aim is to evaluate the long-term safety of levetiracetam and car-
bamazepine in monotherapy.  
Conversion (2 to 6 weeks) to open label levetiracetam
2)  Study N01127, intended to allow subjects from N01061 or N01093 to con-
tinue to receive levetiracetam (including subjects previously exposed to car-
bamazepine who switched to levetiracetam). The aim is to evaluate the long-
term (around 4 years) safety of levetiracetam as per adverse events reporting.  
 
3) Study N01091, an open label Named Patient program
One additional study is ongoing, N01175, a phase IIIb therapeutic confirmatory, 
open-label, multicentre, randomized, community-based trial investigating the ef-
ficacy and safety of levetiracetam compared to valproic acid and carbamazepine 
as monotherapy in subjects with newly diagnosed epilepsy. 
So, for an individual subject the maximum du-
ration of the study was 121 weeks. All patients 
dropping out of the evaluation period were 
presumed not having achieved a 6-month sei-
zure freedom and were consequently counted 
as non-seizure free.
Convincing outcomes 
The primary efficacy variable was the propor-
tion of the per-protocol subjects with 6-month 
seizure freedom at the last evaluated dose. Of 
the 472 patients who adhered to the treatment 
protocol, 73.0% of levetiracetam and 72.8% of 
carbamazepine-CR patients were seizure-free 
for six months.
Amongst the patients who completed the 
maintenance phase of the study, 56.6% of 
those in the levetiracetam group and 58.5% in 
the carbamazepine CR-group were seizure-free 
for 12 months. 
It is noteworthy that significantly fewer pa-
tients on levetiracetam needed to stop treat-
ment or change their dose because of an ad-
verse event than those taking carbamazepine 
CR (16.1% versus 23.0%; p=0.046).
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*  Within the ITT population, it was possible to identify those reporting partial seizures Type IC 
(partial onset seizures with secondary generalisation).
** Adjusted Difference (LEV-CBZ) 95%CI
